Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lorenzo Gerratana

Showing results (31-40 of 127) with videos related to

Pageof 13
Sort By:
International Journal of Molecular Sciences|May 31, 2020
Bevacizumab or PARP-Inhibitors Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-AnalysisMichele Bartoletti, Giacomo Pelizzari, Lorenzo Gerratana, et al.
Therapeutic Drug Monitoring|February 17, 2024
Therapeutic Monitoring of Palbociclib, Ribociclib, Abemaciclib, M2, M20, and Letrozole in Human Plasma: A Novel LC-MS/MS MethodBianca Posocco, Martina Zanchetta, Marco Orleni, et al.
Expert Review of Anticancer Therapy|June 10, 2024
Is ctDNA ready to outpace imaging in monitoring early and advanced breast cancer?Lorenzo Foffano, Riccardo Vida, Alberto Piacentini, et al.
Cancer Treatment Reviews|June 1, 2025
Key decision factors in second-line therapy: Expert insights on HR+/HER2-metastatic breast cancer post-CDK4/6 inhibitor progressionRoberto Buonaiuto, Andrea Botticelli, Carmen Criscitiello, et al.
Frontiers in Pharmacology|September 23, 2024
Exploring pharmacokinetic variability of palbociclib in HR+/HER2- metastatic breast cancer: a focus on age, renal function, and drug-gene interactionsElena Peruzzi, Bianca Posocco, Lorenzo Gerratana, et al.
International Journal of Molecular Sciences|October 16, 2024
Quantification of Letrozole, Palbociclib, Ribociclib, Abemaciclib, and Metabolites in Volumetric Dried Blood Spots: Development and Validation of an LC-MS/MS Method for Therapeutic Drug MonitoringEleonora Cecchin, Marco Orleni, Sara Gagno, et al.
Journal of Neuro-Oncology|August 23, 2018
Defining a prognostic score based on O6-methylguanine-DNA methyltransferase cut-off methylation level determined by pyrosequencing in patients with glioblastoma multiformeElisa De Carlo, Lorenzo Gerratana, Giovanna De Maglio, et al.
Cancers|January 11, 2022
Single-Cells Isolation and Molecular Analysis: Focus on HER2-Low CTCs in Metastatic Breast CancerPaolo D'Amico, Carolina Reduzzi, Wenan Qiang, et al.
Dermatology and Therapy|March 31, 2025
Risk Assessment in Atopic Dermatitis: Guidance from a Multidisciplinary Expert PanelAlessandra Narcisi, Vito Di Lernia, Maria Esposito, et al.
The Oncologist|May 6, 2014
Measures of outcome in metastatic breast cancer: insights from a real-world scenarioMarta Bonotto, Lorenzo Gerratana, Elena Poletto, et al.
Pageof 13

Showing results (31-40 of 127) with videos related to

Sort By:
Pageof 13
International Journal of Molecular Sciences|May 31, 2020
Bevacizumab or PARP-Inhibitors Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-AnalysisMichele Bartoletti, Giacomo Pelizzari, Lorenzo Gerratana, et al.
Therapeutic Drug Monitoring|February 17, 2024
Therapeutic Monitoring of Palbociclib, Ribociclib, Abemaciclib, M2, M20, and Letrozole in Human Plasma: A Novel LC-MS/MS MethodBianca Posocco, Martina Zanchetta, Marco Orleni, et al.
Expert Review of Anticancer Therapy|June 10, 2024
Is ctDNA ready to outpace imaging in monitoring early and advanced breast cancer?Lorenzo Foffano, Riccardo Vida, Alberto Piacentini, et al.
Cancer Treatment Reviews|June 1, 2025
Key decision factors in second-line therapy: Expert insights on HR+/HER2-metastatic breast cancer post-CDK4/6 inhibitor progressionRoberto Buonaiuto, Andrea Botticelli, Carmen Criscitiello, et al.
Frontiers in Pharmacology|September 23, 2024
Exploring pharmacokinetic variability of palbociclib in HR+/HER2- metastatic breast cancer: a focus on age, renal function, and drug-gene interactionsElena Peruzzi, Bianca Posocco, Lorenzo Gerratana, et al.
International Journal of Molecular Sciences|October 16, 2024
Quantification of Letrozole, Palbociclib, Ribociclib, Abemaciclib, and Metabolites in Volumetric Dried Blood Spots: Development and Validation of an LC-MS/MS Method for Therapeutic Drug MonitoringEleonora Cecchin, Marco Orleni, Sara Gagno, et al.
Journal of Neuro-Oncology|August 23, 2018
Defining a prognostic score based on O6-methylguanine-DNA methyltransferase cut-off methylation level determined by pyrosequencing in patients with glioblastoma multiformeElisa De Carlo, Lorenzo Gerratana, Giovanna De Maglio, et al.
Cancers|January 11, 2022
Single-Cells Isolation and Molecular Analysis: Focus on HER2-Low CTCs in Metastatic Breast CancerPaolo D'Amico, Carolina Reduzzi, Wenan Qiang, et al.
Dermatology and Therapy|March 31, 2025
Risk Assessment in Atopic Dermatitis: Guidance from a Multidisciplinary Expert PanelAlessandra Narcisi, Vito Di Lernia, Maria Esposito, et al.
The Oncologist|May 6, 2014
Measures of outcome in metastatic breast cancer: insights from a real-world scenarioMarta Bonotto, Lorenzo Gerratana, Elena Poletto, et al.
Pageof 13